Eiger Corporate News

»Eiger Corporate News
14 03, 2019

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

2019-03-14T22:50:48+00:00

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Began 2019 with $100.4 million in cash, cash equivalents & short-term investmentsEnrollment of Phase 3 D-LIVR Study in HDV planned by end of 2019NDA and MAA filings for Progeria and Progeroid Laminopathies planned in 2019 PALO ALTO, Calif., March 14, 2019 [...]

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update2019-03-14T22:50:48+00:00
27 02, 2019

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer

2019-02-27T14:57:39+00:00

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer PALO ALTO, Calif., February 27, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Dr. Stephana Patton as the Company’s General [...]

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer2019-02-27T14:57:39+00:00
7 01, 2019

Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors

2019-01-07T15:50:15+00:00

Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors PALO ALTO, Calif., January 7, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, announced today the appointment of Christine Murray, MS, RAC to its Board of Directors. [...]

Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors2019-01-07T15:50:15+00:00
11 12, 2018

Eiger BioPharmaceuticals Reports on 2018 R&D Day

2018-12-11T21:30:44+00:00

Eiger BioPharmaceuticals Reports on 2018 R&D Day Late Stage Rare and Ultra-Rare Disease Pipeline Advancing >$100M in Cash Available to Achieve Key Milestones PALO ALTO, Calif., December 11, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced recent accomplishments reported at [...]

Eiger BioPharmaceuticals Reports on 2018 R&D Day2018-12-11T21:30:44+00:00
3 12, 2018

Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer

2018-12-04T11:27:49+00:00

Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer PALO ALTO, Calif., December 3, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the appointment of Sri Ryali as the company’s Chief Financial Officer.  Mr. Ryali brings over fifteen [...]

Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer2018-12-04T11:27:49+00:00
9 11, 2018

Eiger Bio Reports Third Quarter 2018 Financial Results

2018-11-09T14:32:39+00:00

Eiger Bio Reports Third Quarter 2018 Financial Results - HDV Phase 3 D-LIVR study start in 2018 and Progeria NDA planned in 2019 - Over $100 million in cash to advance late stage rare disease pipeline PALO ALTO, Calif., November 9, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted [...]

Eiger Bio Reports Third Quarter 2018 Financial Results2018-11-09T14:32:39+00:00
23 10, 2018

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock

2018-11-07T11:44:18+00:00

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PALO ALTO, Calif., October 23, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the accelerated development and commercialization of targeted therapies for rare and ultra-rare diseases, announced today the pricing of its previously announced underwritten public offering.  The Company announced [...]

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock2018-11-07T11:44:18+00:00
22 10, 2018

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock

2018-10-23T10:38:36+00:00

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PALO ALTO, Calif., October 22, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that it has commenced an underwritten public offering of its common stock.  Eiger intends to grant the underwriters a 30-day [...]

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock2018-10-23T10:38:36+00:00
25 09, 2018

Eiger BioPharmaceuticals to Participate in Investor Conferences

2018-09-25T13:50:24+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences PALO ALTO, Calif., September 25, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present at two investor conferences in October in New York City. Cantor Fitzgerald 4th [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences2018-09-25T13:50:24+00:00
10 08, 2018

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results

2018-08-10T13:36:31+00:00

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results  PALO ALTO, Calif., August 10, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three and six months ended June 30, 2018 and provided a business update. Key Achievements 2Q 2018 To [...]

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results2018-08-10T13:36:31+00:00